Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint applications [10][11] - The year 2026 is identified as a critical year for the confirmation of IO combined with ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological tumors [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and other cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody with multiple ongoing trials [32] Section 2: Confirming the Year of "IO+ADC" Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO combined with ADC is competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, emphasizing their potential in the oncology sector [11][56]

Core Viewpoint - The article highlights the investment philosophy and strategies of Zhang Qing, a prominent female fund manager with nearly 20 years of experience, emphasizing her focus on fundamental analysis and long-term value creation in investment decisions [2][3][4]. Group 1: Investment Philosophy - Zhang Qing's investment approach is characterized by a deep understanding of business models and a focus on long-term value, aiming to calculate risks and potential returns meticulously [6][8]. - She emphasizes the importance of "growth alpha" and prefers to make contrarian investments when mispricing occurs in the market [8][27]. - The investment philosophy is rooted in a rigorous fundamental analysis framework, which has been effective over time and across market cycles [3][10]. Group 2: Experience and Background - Zhang Qing began her career in 1996 with a focus on fundamental analysis and was one of the earliest CFA charterholders in China [4][10]. - Her experience includes managing sovereign wealth fund accounts, making her one of the longest-serving female fund managers in this domain [3][21]. - The investment team at her firm has a strong emphasis on continuous learning and adapting to market changes, which has contributed to their long-term success [81][82]. Group 3: Market Insights and Trends - The article discusses the current market environment, highlighting the challenges and opportunities in sectors such as insurance and innovative pharmaceuticals [44][50]. - Zhang Qing notes that the insurance sector is currently undervalued due to market pessimism, but long-term fundamentals remain strong [45][49]. - In the innovative drug sector, there is a focus on companies with solid cash positions and promising clinical data, indicating a potential for significant returns as the market adjusts its expectations [50][51]. Group 4: Strategic Focus Areas - The investment strategy for 2026 is centered around two main themes: the growth driven by AI and new productive forces, and the continued opportunity in value stocks, particularly in the insurance sector [62][63]. - The firm is also exploring opportunities in sectors like semiconductors and renewable energy, which are expected to benefit from structural changes in the economy [58][60]. - Zhang Qing emphasizes the importance of understanding macroeconomic trends and government policies in shaping investment decisions [77][78].

Core Viewpoint - The performance forecasts for A-share companies in 2025 indicate a significant recovery in the domestic economy, with notable profit growth disparities across different industries and companies, providing essential insights for investment strategies in 2026 [1] Group 1: Performance Highlights - As of January 27, 2026, 1,061 listed companies have disclosed their annual performance forecasts, with 259 companies expecting net profit growth exceeding 100%, accounting for 24.4% of the total [1] - Among these, 48 companies anticipate growth rates over 200%, with some leading firms reporting increases exceeding 1,000% [1] - High-growth companies are primarily concentrated in sectors such as computing power, new energy, chemicals, pharmaceuticals, and robotics, reflecting a clear industry clustering effect [2] Group 2: Sector Analysis - Companies with net profit growth exceeding 50% are mainly found in semiconductor, photovoltaic equipment, innovative pharmaceuticals, and automation equipment sectors, benefiting from policy support, demand recovery, and technological breakthroughs [2] - For instance, Demingli in the storage chip sector expects a median net profit of 1.349 billion yuan, a year-on-year increase of 106.27%, driven by a recovery in the global storage market [2] - Estun, a leader in humanoid robotics, is projected to achieve a net profit of 275 million yuan, with a growth rate of 105.38%, primarily due to increased revenue from industrial robotics [2] Group 3: Policy and Market Drivers - The exceptional performance is attributed to dual drivers of policy benefits and market demand, alongside significant operational optimizations by companies [3] - Since 2025, China has implemented various policies to support advanced manufacturing, technological innovation, and consumer recovery, enhancing market opportunities for relevant industries [3] - Shanghai Electric anticipates a 61.31% year-on-year increase in net profit, marking a turnaround after four consecutive years of losses, attributed to improvements in its main business [3] Group 4: Profitability and Growth Quality - The earnings forecasts reveal a pattern of strong performance across large, medium, and small-cap companies, with notable differentiation in growth quality [4] - Among the disclosed forecasts, 11 companies expect net profits exceeding 5 billion yuan, with Zijin Mining leading at 51 billion yuan [4] - Some companies, like Nanfang Precision, project a staggering 1,273% increase in net profit, largely due to non-recurring gains, contrasting with firms like Shanghai Yizhong and Estun that rely on core business growth [4] Group 5: Market Impact - The concentrated disclosure of performance forecasts has significantly influenced the capital market, with high-growth stocks attracting substantial investor interest [5] - Nearly half of the 259 companies with over 100% profit growth have seen their stock prices rise by over 10% since January [5] - Institutional investors are adjusting their portfolios, focusing on sectors like electronics, new energy, chemicals, and pharmaceuticals, while also noting that some companies face performance pressures [5]

1月28日，港股市场小幅高开。 新股方面，鸣鸣很忙（HK01768）上市首日高开超88%，股价报445港元，总市值达959亿港元。 | 鸣鸣很忙 (01768) CAS | | | | | | | --- | --- | --- | --- | --- | --- | | 445 01010 1208.400 | | +88.08% | | + @ | | | 行情报价 | | | | | | | 成交量 | 300万股 | 最高 | 445.000 今开 | | 445.000 | | 成交额 | 12.9亿 | 最低 | 445.000 昨收 | | 236.600 | | 买量 | 200股 | 振幅 | 0.00% 换手 | | 1.40% | | 变量 | 12600股 | 均价 | 430.674 | | | | 每股收益TTM 9.561 | | 市盈率TM | 46.54 | 每股净资产 36.706 | | | 总股本 总市值 959亿港元 | 2.16亿 | | 市净率 | | 12.123 | | 港股股本 2.14亿 港股市值 950亿港元 | | | | | | 鸣鸣很忙是一家成熟且 ...

Core Viewpoint - The market is currently experiencing a narrow range of fluctuations, with a divergence in individual stock performances, indicating a potential shift from theme-driven to fundamental-driven market dynamics, while technology growth remains the main focus [1] Group 1: Market Overview - The index continued to fluctuate within a narrow range, with over 3,400 stocks declining and only about 1,900 stocks rising, indicating a significant divergence in stock performance [1] - The total trading volume on Tuesday was 2.9 trillion yuan, which is more than a 10% decrease compared to Monday, reflecting a notable contraction in market activity [1] - Since the end of the continuous rise on January 13, the index has entered a period of adjustment, characterized by a relatively mild overall adjustment range [1] Group 2: Future Outlook - The market is expected to shift from theme-driven momentum to a focus on fundamentals, with technology growth remaining the primary driver [1] - The main driving factors for the spring market are anticipated to be an increase in market risk appetite, with future hotspots likely to be technology growth sectors supported by fundamentals [1] - Key sectors to watch include semiconductors, batteries, AI hardware, and innovative pharmaceuticals, which are expected to benefit from this shift [1] Group 3: Hot Sectors - In January, technology and raw material price increases are expected to dominate, with a strong likelihood of technology growth sectors outperforming [2] - Short-term catalysts such as commercial aerospace, brain-computer interfaces, and low-altitude economy are expected to maintain investor interest [2] - The rise in raw material prices, particularly in small metals, energy metals, and new chemical materials, is seen as a derivative opportunity from the technology investment boom [2] Group 4: Specific Trends - The trend in AI hardware is firmly established, with a continuous increase in the token usage of major AI models, indicating a peak in AI applications expected by 2026 [2] - The domestic production of robots and their integration into daily life is a confirmed trend for 2026, with opportunities arising in sensors, controllers, and dexterous hands [2] - The trend towards semiconductor localization is ongoing, with a focus on semiconductor equipment, wafer manufacturing, semiconductor materials, and IC design [2] - The demand for new energy materials is rapidly increasing due to domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to continue until 2026 [2] - Innovative pharmaceuticals are entering a recovery phase after nearly four years of adjustment, with positive net profit growth for four consecutive quarters since Q3 2024, and a fundamental turning point expected in 2025 [2]

【导读】源乐晟举办2026年度策略会，曾晓洁、杨建海最新发声 近日，老牌私募源乐晟举办2026年度策略会，源乐晟资产创始人曾晓洁与源乐晟合伙人杨建海分享了对 2026年市场的展望及行业观察。 曾晓洁与杨建海均认为，目前无需担忧"AI泡沫"，2026年或成为AI行业标志性的一年。当前消费板块较 难出现大贝塔行情，但新消费领域结构性机会持续存在。化工行业当前估值处于低位，产品价格具备反 弹基础，化工板块具备较强的性价比。 整体而言，2026年有望走出"慢牛"行情，但"慢牛"不代表没有波动。在风险方面，地缘政治风险、美联 储降息滞后等因素仍需警惕。 消费行业仍有结构性机会 化工板块具有较强的性价比 "在新消费领域，每年都会有结构性的机会。"杨建海表示，如餐饮中的一些细分赛道，在新兴业态下的 翻台率大幅突破过往。新消费领域不乏这类结构性机会，但这类机会的天花板相较以往更低，相关标的 市值达到一定程度后，其发展的持续性会引发担忧。 他认为，白酒行业那种长期持有"躺平"的逻辑已不再适用于新消费投资，而是需要每年在不同SKU中筛 选出当期锐度最强的方向，同时紧密跟踪标的变化、动态评估。 在杨建海看来，当前消费板块较难出现大 ...

Core Viewpoint - The report highlights the significant growth driven by technology in certain sectors, while also noting the substantial losses due to cyclical downturns in others [1] Performance Growth Highlights - **Zhongwei Company (688012)**: Expected net profit between 208 million to 218 million yuan, a year-on-year increase of 28.74% to 34.93%, driven by increased recognition of plasma etching equipment and a surge in market demand [5] - **Lianchuang Optoelectronics (600363)**: Expected net profit between 43.5 million to 53.2 million yuan, a year-on-year increase of 80.36% to 120.57%, attributed to significant growth in laser business and improved profitability in traditional sectors [6] - **Ruixin Microelectronics (603893)**: Expected net profit between 102.3 million to 110.3 million yuan, a year-on-year increase of 71.97% to 85.42%, driven by rapid growth in the AIoT market and recognition of new AI technology [7] - **Sangfor Health (688336)**: Expected net profit around 290 million yuan, a year-on-year increase of approximately 311.35%, due to a significant collaboration with Pfizer and advancements in clinical research [8] - **Pulite (002324)**: Expected net profit growth of 155.76% to 194.73%, driven by the demand for high polymer materials in the automotive lightweight trend [9] - **Tonghua Dongbao (600867)**: Expected net profit around 124.21 million yuan, turning from loss to profit, driven by market share gains in insulin products [10] - **Suotong Development (603612)**: Expected net profit between 73 million to 85 million yuan, a year-on-year increase of 167.98% to 212.03%, due to rising prices and demand in the prebaked anode industry [11] Major Performance Declines - **China Shipbuilding Technology (600072)**: Expected net loss between -260 million to -340 million yuan, a year-on-year decline of over 24 times, due to cyclical downturns in shipbuilding and high material costs [12] - **Silver Nonferrous Metals (601212)**: Expected net loss between -45 million to -67.5 million yuan, transitioning from profit to loss due to legal disputes affecting financial performance [13] - **China Metallurgical Group (601618)**: Expected net profit between 130 million to 160 million yuan, a year-on-year decline of 76.28% to 80.73%, impacted by the downturn in the construction industry [14] - **Jindi Group (600383)**: Expected net loss between -1.11 billion to -1.35 billion yuan, with increased losses due to declining sales and inventory impairments [15] - **Jianfa Co. (600153)**: Expected net loss between -1 billion to -520 million yuan, transitioning from profit to loss due to increased impairments in real estate [16] Industry Trend Analysis - **Technology and Innovation-Driven Sectors**: Companies in semiconductor equipment, laser military applications, and innovative pharmaceuticals are experiencing rapid growth due to high demand in AIoT, national defense, and biomedicine [23] - **Traditional Cyclical Industries**: Sectors like coal and engineering machinery are facing significant adjustments due to demand shortages and price declines, leading to widespread performance pressures [24] - **Pharmaceutical Industry Disparities**: Innovative drugs are seeing explosive growth through external licensing, while traditional formulations and raw materials are significantly impacted by procurement policies [24] - **External Environment Uncertainties**: Factors such as international trade tensions and regulatory changes are significantly affecting corporate performance, necessitating enhanced risk management [24] - **Asset Quality Risks**: Many companies are reporting substantial asset impairment provisions, indicating potential inefficiencies in previous investments [24]

Core Viewpoint - The A-share market is experiencing a rebound, particularly in the innovative pharmaceutical sector, with significant capital inflow into the ETF focused on innovative drugs, indicating strong investor confidence in this segment [1][5]. Group 1: Market Performance - The A-share market showed a positive trend on January 27, with the Shanghai Composite Index fluctuating upwards, closing with a gain [1]. - The ETF for innovative drugs, Huatai-PineBridge (589120), saw a 0.71% increase in the afternoon session, attracting over 40 million yuan in capital over the past five days [1]. Group 2: Stock Performance - The majority of the index component stocks for the innovative drug ETF experienced gains, with notable performances from companies such as Sanofi (10.93% increase) and Junshi Biosciences (nearly 8% increase) [2][3]. - The top ten component stocks of the ETF include companies like BeiGene and I-Mab, with varying weightings and performance metrics [4]. Group 3: Industry Outlook - The innovative pharmaceutical sector is witnessing a recovery in performance, with over 50 companies expected to report profits for 2025, driven by improved industry conditions and favorable policies [5]. - As of January 26, more than 90 A-share innovative and biopharmaceutical companies have disclosed their 2025 earnings forecasts, with 53 companies expected to be profitable [5]. Group 4: Strategic Developments - Significant collaborations, such as the partnership between Sanofi and Pfizer, are contributing to substantial revenue growth, with Sanofi projecting a net profit of 2.9 billion yuan for 2025, marking a 311.35% increase year-on-year [5]. - The innovative drug sector is entering a phase of capital influx, research iteration, and value realization, indicating a positive cycle for the industry [8]. Group 5: Global Competitiveness - The Chinese innovative drug sector is becoming increasingly competitive on a global scale, with a record-breaking outbound transaction volume exceeding 135 billion USD in 2025 [7]. - China is expected to play a leading role in the next cycle of global innovation in pharmaceuticals, with a focus on areas such as PD-1 dual antibodies and antibody-drug conjugates [8].

Core Viewpoint - The Hong Kong stock market is experiencing an upward trend, with a focus on the AI technology sector as a key area for investment opportunities [1] Group 1: Market Trends - The Hong Kong Technology ETF (513020) rose over 1%, indicating positive market sentiment towards AI technology [1] - Southbound capital is significantly flowing into the information technology sector, making it one of the main industries for net inflows in the Hong Kong Stock Connect [1] Group 2: Sector Performance - The Hong Kong Technology ETF tracks the Hong Kong Stock Connect Technology Index (931573), which includes core assets in sectors such as internet, semiconductors, innovative pharmaceuticals, and new energy vehicles [1] - The Hong Kong Stock Connect Technology Index has outperformed the Hang Seng Technology Index, with a cumulative return of 224.25% since the base date at the end of 2014, compared to 83.87% for the Hang Seng Technology Index, indicating a significant excess return of over 140% [1]